CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia. Fu B, Liao J, Chen S, Li W, et al. Nat Med 2022;28:1573-1580.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fu B, Liao J, Chen S, Li W, et al. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia. Nat Med 2022;28:1573-1580.
PMID: 35922667